A nationwide cohort study in South Korea demonstrated that patients with type 2 diabetes treated with dapagliflozin experienced a 12% to 17% reduced risk of incident AF compared with empagliflozin use.14 Conversely, a large cohort study reported that empagliflozin was associated with a 10% lower risk of the composite outcome of all-cause mortality or hospitalization compared with dapagliflozin.12 However, these studies had limitations, including missing data on the NT-proBNP level and LVEF. This evidence concerns the gene NPPB and type 2 diabetes mellitus.